Articles by Emily Menendez
Germline genetic testing is underused for patients with prostate cancer, despite many being eligible for the procedure.
Enzalutamide with [177Lu]Lu-PSMA-617 improved OS and HRQOL, along with PSA PFS.
A recent proof-of-concept study has further evaluated the efficacy of PSMA-guided MDT for oligometastatic RCC.
COSMIC-021 began in 2017 to analyze the effects of cabozantinib alone or with atezolizumab for advanced solid tumors.
This newly developed assay can assess the genomic profile of ctDNA in patients with advanced UC.
The combination therapy provided similar survival rates and toxicity in an older patient population.
The combination demonstrated a manageable safety profile with evidence of EZH2 pharmacodynamic inhibition and OR.
Preliminary results of the study showed promising efficacy and safety with neoadjuvant treatment with DV plus toripalimab.
EV with erdafitinib is a feasible combination with the ability to provide promising antitumor activity in mUC.
Previous data from the phase II CALYPSO study has demonstrated the efficacy of durvalumab in combination with savolitinib.
A long-term efficacy benefit was seen with nivolumab plus cabozantinib over sunitinib, with no new safety signals.
The EPIC-A trial has demonstrated the efficacy and safety of cemiplimab combined with platinum-based chemotherapy for la/mPC.
The interim analysis of the RETAIN-2 trial demonstrated a 46% pT0 rate among those undergoing cystectomy.
New research evaluated the efficacy and safety of durvalumab with intravesical gem/doce in a cohort from ADAPT-BLADDER.
The first-line treatment of aRCC with cabozantinib, nivolumab and ipilimumab continued to provide PFS and ORR benefits.
Nivolumab demonstrated sustained DFS benefits across all patients with MIBC and in prior NAC subgroups.
C2D1 ctDNA fraction may be more strongly associated with rPFS and OS than baseline ctDNA fraction.
In 53.3% of cases, PSMA PET positively identified bone disease despite negative findings on bone scintigraphy.
Patients with mHSPC who are younger, have a high BMI, or have low-volume disease may benefit more from treatment with ARPIs.
Specificity findings varied, but some studies suggested similar or slightly higher rates in favor of MRI.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.